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IMPORTANCE Since 2001, there has been a rapid adoption of positron emission tomography
(PET) for diagnosis and American Joint Committee on Cancer (AJCC) staging of head and
neck cancer (HNC) without data describing improved clinical outcomes.
OBJECTIVE To determine the association between increased use of PET and stage and/or
survival for patients with HNC in the managed care environment.
DESIGN, SETTING, AND PARTICIPANTS Adult patients diagnosed as having HNC (n = 958) from
2000 to 2008 at 4 integrated health systems were identified via tumor registries linked to
administrative data. The AJCC stage distribution, patient and treatment characteristics, and
survival between pre-PET era (2000-2004) vs PET era (2005-2008) and use of PET vs no
use of PET during the PET era were compared. The AJCC stages were categorized to
represent localized (stage I or II), locally advanced (stage III, IVA, or IVB), and metastatic (stage
IVC) disease.
INTERVENTIONS Treatments were determined by billing codes for surgery, radiation
treatment, and chemotherapy.
MAIN OUTCOMES AND MEASURES The primary outcome for this study was the use of PET.
Secondary outcomes included treatment received and 2-year survival. A logit model
estimated the effects of PET on diagnosis of locally advanced disease. Kaplan-Meier
estimates described overall survival differences between PET and non-PET. Cox regression
evaluated the association of PET on survival in patients with locally advanced disease.
RESULTS An association between PET and locally advanced disease was found (odds ratio,
2.86 [95% CI, 1.90-4.29) (P < .001). Two-year overall survival for patients with locally
advanced disease with and without PET was 52% and 32%, respectively (P = .004), but there
was no difference for all stages (P = .69). On Cox proportional hazard regression, PET had no
association with survival in patients with locally advanced disease (hazard ratio, 1.208 [95%
CI, 0.778-1.877]) (P = .40).
CONCLUSIONS AND RELEVANCE The increasing use of PET among patients with HNC is
associated with a greater number of patients with higher-stage disease and a dilution of the
population with higher-stage disease with patients who have a better prognosis. Thus, the
improved survival in patients with locally advanced disease likely reflects selection bias and
stage migration. Further research on PET use among patients with HNC is necessary to
determine if it results in improved treatment for individual patients.
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I n 2001 the Centers for Medicare and Medicaid Services(CMS) began to cover fluorodeoxyglucose (FDG) positronemission tomography (PET) for diagnosing, staging, and re-
staging of head and neck cancer (HNC). Multiple studies have
demonstrated the increased sensitivity of FDG PET over com-
puted tomography (CT) for detecting primary tumors, re-
gional nodal disease, and distant metastases.1-7 This improve-
ment in diagnostic staging often results in changes in
therapeutic recommendations for surgical and radiation treat-
ment as well as changes to radiation treatment fields.8-11 Be-
cause of potential treatment changes and prognostic informa-
tion, as well as patient and physician preference, FDG PET has
been rapidly adopted for managing HNC.12 However, whether
these changes result in better clinical outcomes is not en-
tirely known.
Because FDG PET is more sensitive than CT,3 it often leads
to patients being assigned a higher stage than if they were staged
with CT alone.9 For example, a recent study reported that 17%
of patients with HNC were assigned a higher stage after under-
going FDG PET compared with CT alone.9 The tendency for FDG
PET to lead to “up-staging” of HNC may lead to better stage-
specific survival: ie, FDG PET–staged patients with higher-
stage disease having a better prognosis than comparable CT
alone–staged patients. This dilution effect is often referred to as
the Will Rogers phenomenon, or stage migration.13 The concept
of stage migration was first described by Feinstein and
colleagues13 in a cohort of patients with lung cancer. The re-
searchers found that patients who had been diagnosed using CT,
radionuclide scanning, and ultrasonography had higher 6-month
survival and stage-specific survival than those who were diag-
nosed based on “old” diagnostic tools. However, they demon-
strated that if all of the patients were staged based on clinical
symptoms that were unaltered by new diagnostic techniques,
the 2 cohorts had similar survival periods. Thus, they hypoth-
esized that use of the new technologies caused a migration of
better-prognosis patients into higher stages of disease, leading
to the appearance of improved survival length in both lower- and
higher-staged patients rather than improvement in individual
patient care. They named this the Will Rogers phenomenon af-
ter the humorist who reportedly once joked about a geographic
migration that occurred during the Great Depression: “When the
Okies left Oklahoma and moved to California, they raised the av-
erage intelligence level in both states.” While the quote attribu-
tion to Will Rogers cannot be documented, the statistical con-
cept it articulates is solid.
The hypothesis of the present study is that the increased
use of FDG PET over time is associated with the appearance
of improved stage-specific survival due to a stage migration
phenomenon. To test this hypothesis, we analyzed the use of
FDG PET in a large multisite sample of managed care patients
in the United States.
Methods
Study Population and Setting
The study involved only retrospective administrative
data review, so patient informed consent was waived.
This analysis was conducted within 4 large, nonprofit, inte-
grated health systems: Group Health Cooperative (Seattle,
Washington), Health Alliance Plan–Henry Ford Health
System (Detroit, Michigan), Kaiser Permanente Colorado
(Denver), and Kaiser Permanente Northwest (Portland,
Oregon). Institutional review boards at each of the 4 partici-
pating health systems approved all aspects of the study pro-
tocol. These plans are all members of the Cancer Research
Network (National Cancer Institute [NCI] Cooperative
Agreement No. U19 CA79689, Increasing Effectiveness of
Cancer Control Interventions), an initiative of the NCI
designed to conduct research on cancer prevention, early
detection, treatment, long-term care, surveillance, and can-
cer communication dissemination and implementation
research.
Data available from each health system’s tumor registry
were used to identify patients older than 18 years who were
diagnosed as having HNC between 2000 and 2008. We clas-
sified patients by tumor site as follows: oral cavity (Interna-
tional Classification for Diseases for Oncology [ICD-O] codes
C000-C009 and C019-C069), oropharynx (ICD-O codes
C090-C099 and C100-C109), nasopharynx (ICD-O codes
C110-C119), larynx and/or hypopharynx (ICD-O codes C129-
C139 and C320-C329), salivary gland (ICD-O codes C079-
C089), and sinuses and/or pharynx unspecified (ICD-O
codes C140, C142, and C148). Patients eligible for study
inclusion were those continuously enrolled in the health
plan for the 12-month period preceding their date of cancer
diagnosis. Patients whose stage of disease at the time of
diagnosis was not available were excluded. Patients were
also excluded if they had a previous diagnosis of invasive
cancer. For HNC diagnosis and staging, sample patients
were observed from an index date, defined as 60 days pre-
ceding their HNC diagnosis date, until the earliest of the fol-
lowing end points: death, health plan disenrollment, 5 years
after the initial cancer diagnosis, or the end of the follow-up
period (December 31, 2008). Comorbidities were identified
from a period of 12 months prior to diagnosis.
Data Sources and Measures
Automated electronic medical record (EMR) data linked to
tumor registry data were accessed to obtain tumor site, age
at diagnosis, sex, date of cancer diagnosis, stage at diagno-
sis, and comorbidities within the 12-month period preced-
ing diagnosis for each patient. We defined the disease stages
into 3 clinically relevant groups: localized (American Joint
Committee on Cancer [AJCC] stages I and II), locally
advanced (stages III, IVA, and IVB), and metastatic (stage
IVC). Administrative data and EMRs were reviewed between
the patient’s index date and end date to compute receipt of
imaging services and treatment with surgery, chemo-
therapy, and radiation. Receipt of imaging tests was ascer-
tained through Current Procedural Terminology (CPT)
codes 78111 through 78116 for PET and CPT codes 70450,
70460, 70470, 70486, 70490 through 70492, 71250, 71260,
and 71270 for CT. Receipt of treatment type was determined
by billing codes and timing of treatment within 120 days fol-
lowing diagnosis. The Deyo adaptation of the Charlson
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comorbidity index was constructed using inpatient and out-
patient diagnostic information available in the 12-month
period preceding diagnosis.14 Because FDG PET was not
used in these organizations before 2005,15 we defined the
PET era as the period from 2005 through 2008 and the pre-
PET era as 2000 through 2004. For each patient, we defined
the initial phase to include the staging and active treatment
periods, beginning 30 days before diagnosis and ending 60
days following the first diagnosis. These dates were chosen
based on variability of diagnosis date compared with first
treatment as well as timing between surgery (which was
often the same as diagnosis date) and first radiation or che-
motherapy treatments. Patients who underwent their first
PET after their first radiation or chemotherapy treatments
and those who underwent first PETs after 60 days from
diagnosis were considered as part of a surveillance group,
and for the purpose of this study were considered in the
no-PET group for staging.
Analytical Approach
The primary end point in this study was the use of FDG PET
among patients with HNC. To establish whether diagnosis
era had an effect on staging and survival, a χ2 test or Wil-
coxon rank sum test (age, comorbidity, and stage) was used
to examine the significance of differences in the distribu-
tions of various characteristics between patients with HNC
in the pre-PET vs PET eras. For survival analysis compari-
son, 2-year product-limit survival estimates via Kaplan-
Meier methods were used. Because the PET-era patients had
significantly less follow-up time, the survival comparison
analysis performed for the PET era vs pre-PET era was lim-
ited to patients in the PET era diagnosed in 2005 and 2006
and having at least 2 years of possible follow-up. A separate
analysis was performed to examine the significance of dif-
ferences in the distributions of various characteristics
between those who underwent PET and those who did not
within the PET era. For these analyses, data from patients
diagnosed from 2005 through 2008 were used. Because of
the differing lengths of follow-up among sample members,
we used the Kaplan-Meier method for estimating overall
survival by stage and FDG PET status (ie, with and without)
during the PET era. We used a Cox proportional hazards
model, which also accounts for the differing length of
follow-up among sample members, to quantify the effects
of FDG PET use among patients with locally advanced dis-
ease, controlling for baseline clinical and sociodemographic
patient characteristics, on the risk of death in the PET
era. The control variables in the Cox Model included the
patient’s tumor site, age at diagnosis, sex, Charlson-Deyo
comorbidity score, and treatment type. We used a logit
model to estimate the association between PET use and
diagnosis of locally advanced disease. For this model, we
pooled patients in both the pre-PET and PET eras. We con-
trolled for PET use, tumor site, age at diagnosis, sex, and
health plan. Analyses were performed using SAS software,
version 9.3 (SAS Institute Inc) and STATA software, version
11.0 (StataCorp LP). Statistical results of P < .01 were consid-
ered to be statistically significant.
Results
Patient and Treatment Characteristics
A total of 958 patients identified in this cohort met the study
inclusion criteria. Forty-six percent were treated in the PET era.
Median patient age was 66 years. Median follow-up for all pa-
tients was 31 months (range, 0.1-109.0 months). The median
follow-up for patients in the pre-PET era was 56 months. For
surviving patients in the PET era, the median follow-up for
those who underwent PET was 22 months, and the median fol-
low-up for those who did not undergo PET was 27 months (see
eFigure 1 in the Supplement). Most patients were men and had
a Charlson comorbidity score of 0. Oral cavity was the most
common primary tumor site, and most patients were diag-
nosed as having localized disease.
Pre-PET Era vs PET Era
Bivariate analyses found no statistically significant differ-
ences in the primary tumor sites, stage, age, sex, or comor-
bidities between patients in the pre-PET era and the PET era
(Table 1). A significant difference in the type of treatments pa-
tients received was detected: less use of surgery (pre-PET era,
66.9% vs PET era, 53.7%) (P < .001) and a trend toward increas-
ing use of chemotherapy during the PET era (pre-PET era, 20.5%
vs PET era, 25.9%) (P = .05). No difference in 2-year overall sur-
vival (OS) rates was found (pre-PET era, 75.5% vs PET era,
74.0%) (P = .34).
PET vs No PET During the PET Era
In the PET era, tumor site was significantly associated with use
of PET for staging (P < .001) (Table 1). Younger patients and
those with later years of diagnosis were more likely to have un-
dergone FDG PET scans (P < .001). Use of FDG PET for staging
purposes has been increasing since 2005 among this cohort
(eFigure 2 in the Supplement). In 2005, about 12.5% of pa-
tients received pretreatment FDG PET scans. By 2008, the per-
centage increased to 34%. Compared with patients who did not
undergo PET, those who underwent PET were more likely to
receive radiation treatment (no PET, 48.3% vs PET, 83.3%
(P < .001), more likely to receive chemotherapy (no PET, 17.5%
vs PET, 43.1%) (P < .001) and less likely to receive no treat-
ment (no PET, 18.8% vs PET, 0%) (P < .001).
PET Association With Staging
Within the PET era cohort, a statistically significant increase
in the number of patients staged as having locally advanced
disease was observed (Table 1 and Figure 1). In oral cavity and
larynx and/or hypopharynx disease, most patients who un-
derwent PET scans were staged as having locally advanced dis-
ease, while those without PET were mostly staged as having
local disease (eFigures 3 and 4 in the Supplement). However,
this was not the case with oropharynx and nasopharynx (eFig-
ures 5 and 6 in the Supplement). In our logit model of clini-
cally important variables, PET scan use was associated with
higher stage of disease. In addition, oropharyngeal cancers
were more likely to be assigned a higher stage than oral cav-
ity cancers (Table 2).
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Patients in PET Era, No. (%)
P ValuePre-PET Era PET Era No PET Used PET Used
Total 522 (54.4) 436 (45.6) NA 292 (67.0) 144 (33.0) NA
Tumor site
Oral cavity 246 (47.1) 186 (42.7)
.49
134 (45.0) 52 (36.1)
<.001
Oropharynx 66 (12.6) 64 (14.7) 22 (7.5) 42 (29.2)
Nasopharynx 21 (4.0) 20 (4.6) 10 (3.4) 10 (6.9)
Larynx and/or hypopharynx 125 (24.0) 97 (22.3) 74 (25.3) 23 (16.0)
Salivary gland 47 (9.0) 50 (11.5) 40 (13.7) 10 (6.9)
Sinuses and/or pharynx
unspecified
17 (3.3) 19 (4.4) 12 (4.1) 7 (4.9)
Age at diagnosis, yb
18-39 13 (2.5) 12 (2.8)
.35
8 (2.7) 4 (2.8)
<.001
40-49 58 (11.1) 43 (9.9) 26 (8.9) 17 (11.8)
50-64 168 (32.2) 170 (39.0) 101 (34.6) 69 (47.9)
65-74 141 (27.0) 95 (21.8) 64 (21.9) 31 (21.5)
≥75 142 (27.2) 116 (26.6) 93 (31.9) 23 (16.0)
Sex
Male 349 (66.9) 286 (65.6)
.68
188 (64.4) 98 (68.1)
.45
Female 173 (33.1) 150 (34.4) 104 (35.6) 46 (31.9)
Charlson comorbidity scoreb
0 324 (62.1) 256 (58.7)
.19
162 (55.5) 94 (65.3)
.051 117 (22.4) 96 (22.0) 67 (23.0) 29 (20.1)
≥2 81 (15.5) 84 (19.3) 63 (21.6) 21 (14.6)
Stageb
I and II 302 (57.9) 227 (52.1)
.06
181 (62.0) 46 (31.9)
<.001III, IVA, or IVB 206 (39.5) 193 (44.3) 103 (35.3) 90 (62.5)
IVC 14 (2.7) 16 (3.7) 8 (2.7) 8 (5.6)
Year of diagnosis




2001 90 (17.2) NA 0 0
2002 97 (18.6) NA 0 0
2003 99 (19.0) NA 0 0
2004 152 (29.1) NA 0 0
2005 NA 110 (25.2) 92 (31.5) 18 (12.5)
2006 NA 109 (25.0) 68 (23.3) 41 (28.5)
2007 NA 119 (27.3) 83 (28.4) 36 (25.0)
2008 NA 98 (22.5) 49 (16.8) 49 (34.0)
Health plan
1 44 (8.4) 93 (21.3)
<.001
63 (21.5) 30 (20.8)
<.001
2 114 (21.8) 78 (17.9) 68 (23.3) 10 (6.9)
3 175 (33.5) 132 (30.3) 75 (25.7) 57 (39.6)
4 189 (36.2) 133 (30.5) 86 (29.5) 47 (32.6)
Treatment
Surgery 349 (66.9) 234 (53.7) <.001 163 (55.8) 71 (49.3) .20
Radiotherapy 323 (61.9) 261 (59.9) .52 141 (48.3) 120 (83.3) <.001
Chemotherapy 107 (20.5) 113 (25.9) .05 51 (17.5) 62 (43.1) <.001
No treatment 55 (10.5) 55 (12.6) .32 55 (18.8) 0 <.001
Deaths 248 (47.5) 112 (25.7) NA 75 (25.7) 37 (25.7) NA
2-Year survival, %c 75.5 74.0 .34 55.5 53.2 .69
Abbreviations: NA, not applicable; OR, odds ratio; PET, positron emission
tomography.
a The pre-PET era was from 2000 through 2004; PET era, 2005 through 2008.
b Age, comorbidity, and stage were compared using Wilcoxon-rank sum test; all
other variables were assessed with the χ2 test.
c Two-year survival based on product-limit survival estimates. For pre-PET era
vs PET era survival comparison, PET era was limited to 2005 and 2006. All
other analyses included patients from 2005 through 2008.
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PET Association With Survival
Within the PET era, no survival difference was found be-
tween those who underwent FDG PET and those who did not
(Figure 2A). A significant increase in stage-specific survival was
detected for patients with locally advanced disease (Figure 2B).
No stage-specific survival differences were found in patients
with local disease (Figure 2C) or metastatic disease (not shown).
Two-year survival for all patients, no PET vs PET, was 55.5%
vs 53.2% (P = .69). Two-year survival for locally advanced dis-
ease, no PET vs PET, was 32.1% vs 52.2% (P = .004). Multivar-
iate Cox regression analysis showed no association between
use of PET in locally advanced disease and survival (hazard ra-
tio, 1.208) (P = .40) (Table 3).
Discussion
In a large multisite cohort of managed care patients, we iden-
tified an increasing trend in the use of pretreatment FDG PET
scans for patients with HNC since 2005. PET scans were asso-
ciated with a larger percentage of patients diagnosed as hav-
ing locally advanced disease and an increase in stage-specific
survival for patients with locally advanced disease. However,
the use of FDG PET scans was not associated with an overall
survival benefit in patients with locally advanced disease on
multivariate analysis. Therefore the survival benefit for lo-
cally advanced disease is more likely a stage migration phe-
nomenon.
Stage migration, or the Will Rogers phenomenon,13 can oc-
cur across disease eras, or even in individual patients. A clini-
cal scenario illustrating this phenomenon is as follows: A pa-
tient is diagnosed as having stage III salivary gland cancer on
the basis of clinical examination and CT. The patient then un-
dergoes a PET-CT scan, which picks up small pulmonary nod-
ules, and the disease is up-staged to IVC. If the patient had not
undergone a PET scan, standard stage III treatment would have
been administered, and this would have been recorded as a
stage III event; metastatic disease would have been diag-
nosed months to years later. However, because of the PET find-
ings, the patient migrates into the stage IVC patient popula-
tion, thus improving the prognosis for the remaining stage III
population. This patient will likely live longer than those pa-
tients who were diagnosed as having symptomatic distant dis-
ease, thus also improving the prognosis for stage IVC pa-
tients. The actual survival for both groups has not changed,
nor has the survival of the individual patient. More recently,
a large SEER-Medicare claims based study16 demonstrated a
similar phenomenon with increased use of FDG PET scans in
non–small-cell lung cancers.
To our knowledge this is the first study to assess FDG PET
use and survival outcomes in patients with HNC using a mul-
tisite EMR-based data set of both younger and older patients.
A single institutional matched retrospective study of 58 pa-
tients who received FDG PET staging prior to chemoradio-
therapy compared with 58 patients who did not receive FDG
PET for staging prior to chemoradiotherapy demonstrated no
difference between local control, regional control, distant me-
tastases, cause-specific survival or overall survival.17 The re-
sults of that study may not be generalizable because of the small
sample size, single institution patient population, and retro-
spective design. Our study also found no difference in overall
survival for the whole group but did find a stage migration phe-
nomenon with a survival difference for those with locally ad-
vanced disease.
A difference in staging and survival was not identified be-
tween the pre-PET and PET eras. This is interesting given the
increasing incidence of human papillomavirus (HPV)–related
oropharyngeal cancers over this period and their associated
higher stages and improved prognoses.18,19 Tobacco use and
Figure 1. Diagnosis Stage in All Patients Across Eras and PET vs No PET
































Localized Locally advanced Metastatic
Localized disease was defined as American Joint Committee on Cancer stage I or
II; locally advanced, stage III, IVA, or IVB; and metastatic, stage IVC disease.
PET indicates positron emission tomography.
Table 2. Logit Model Analysis for the Association of PET Use
With Diagnosis of Locally Advanced Diseasea
Study Variable OR (95% CI) P Value




Female vs male 0.653 (0.484-0.881) .005
Tumor site
Oral cavity 1 [Reference] 1 [Reference]
Oropharynx 3.338 (2.154-5.173) <.001









1 1 [Reference] 1 [Reference]
2 1.455 (0.901-2.351) .13
3 0.709 (0.457-1.099) .12
4 0.626 (0.402-0.976) .04
Abbreviations: OR, odds ratio; PET, positron emission tomography.
a Locally advanced disease is defined as stage III, IVA, or IVB disease (n = 928),
excluding stage IVC. Localized disease (stage I or II) was used as reference.
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HPV status, 2 important variables, were not available in this
cohort, but the lack of improved survival over these eras at least
allows us to rule out era as a cause of increased staging or sur-
vival. The decrease in surgical treatments across eras found
in this study is consistent with other pattern-of-care studies
across these eras.20
Evidence for stage migration in our study includes the im-
proved survival in locally advanced disease (Figure 2B) for
those who undergo FDG PET. However, in contrast to the origi-
nal report of Feinstein et al,13 our study did not find an im-
proved overall survival within the whole cohort or an im-
proved lower stage-specific survival for those who received the
newer diagnostic technology (FDG PET) compared with those
who did not. The theoretical up-staging of worse-prognosis pa-
tients out of the lower-stage population did not appear to im-
prove the survival of patients with localized disease. This may,
in part, reflect the fact that certain HNC sites have a high
enough probability of occult nodal metastases to warrant elec-
Figure 2. Kaplan-Meier Survival Curves Within the PET Era
Stage-specific survival, localized diseaseC








































































































Localized disease was defined as
American Joint Committee on Cancer
stage I or II; locally advanced, stage III,
IVA, or IVB. PET indicates positron
emission tomography.
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tive nodal dissection or irradiation even with a negative FDG
PET finding. Thus, there might not be a major difference in the
treatment volumes or prognoses of those patients remaining
in localized disease population even after FDG PET up-
staging. However, the up-staging of patients with nodal dis-
ease identified only by FDG PET improved the survival of all
patients with nodal disease compared with those with obvi-
ously identified (no FDG PET) locally advanced disease.
One of the potential benefits of a staging FDG PET scan is
the identification of previously unknown metastatic disease.
This could prevent the use of intensive local regional thera-
pies in the setting of previously unknown metastatic disease.
The present study found an increase in the number of PET pa-
tients who received chemotherapy (43.1% vs 17.5%) (P < .001).
However, our study also found that patients who underwent
FDG PET were less likely to receive no treatment compared with
patients who did not undergo FDG PET. This finding is con-
sistent with prospective studies that showed that few pa-
tients have their treatment intent changed to a palliative course
because of FDG PET results.9,10 One limitation, however, is
that we cannot identify which patients did not receive PET
because they were already known to have advanced meta-
static disease. Once a palliative course is already chosen, there
may be no utility to the use of PET.
Although there is a large discrepancy between follow-up
times for pre-PET and PET era patients, there was not as large
a discrepancy between PET and no-PET patients within the PET
era. To address this discrepancy, the interera comparison was
limited such that only patients with at least 2 years of fol-
low-up in the PET era were assessed. For the PET vs no-PET
analyses, we used patients diagnosed from 2005 through 2008
(PET era only) and used Kaplan-Meier and Cox proportional
hazards models, which both account for the differing length
of follow-up among sample members.
This study has several limitations. First, inherent in all ret-
rospective studies relying on administrative databases, our
study is limited by our inability to evaluate intention of FDG
PET scans. Although we limited our definition of pretreat-
ment FDG PET to those who received FDG PET scans 30 days
prior to and 60 days after diagnosis, we do not know whether
these scans were used for diagnostic, staging, treatment plan-
ning, or other reasons. Similarly, the intention of treatment
method use is also assumed based on timing of encounters.
Second, study cohort members were limited to insured indi-
viduals who received their care from 1 of 4 integrated health
care systems. These patients may not be representative of pa-
tients with cancer at other institutions; thus limiting the gen-
eralizability of the findings of this study. Third, this EMR-and-
encounter-based study was only meant to address the
association between FDG PET and up-staging and/or sur-
vival. There are many other ways that FDG PET can clinically
affect patients, including changing radiation treatment
volumes,21,22 detecting primary sites for HNC of unknown
primary,23 and improving surveillance after treatment.24 None
of these clinical outcomes was addressed in this study.
Conclusions
Within this cohort of patients with HNC, FDG PET use ap-
peared to be associated with up-staging at diagnosis and im-
proved survival in patients with locally advanced disease but
no difference in overall survival for the entire cohort. The im-
proved stage-specific survival is likely a reflection of stage mi-
gration. The ability of FDG PET to affect patient management
for individual patients remains an important area of future
research.
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Table 3. Cox Proportional Hazard Model for Death
in Locally Advanced Diseasea
Characteristics HR (95% CI) P Value
Tumor site
Oral cavity 1 [Reference] 1 [Reference]
Oropharynx 0.991 (0.507-1.937) .98
















No treatment 1 [Reference] 1 [Reference]
Surgery 1.031 (0.681-1.561) .88
Radiotherapy 1.028 (0.633-1.670) .91
Chemotherapy 1.973 (1.268-3.072) .003
PET use vs no PET 1.208 (0.778-1.877) .40
Abbreviations: HR, hazard ratio; PET, positron emission tomography.
a Locally advanced disease is defined as stage III, IVA, or IVB disease (n = 399),
excluding stage IVC. Localized disease (stage I or II) was used as reference.
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